David J. Straus, MD | Authors


Updated ECHELON-1 Findings Demonstrate Potential Toxicities of Brentuximab Vedotin Combo in cHL

June 19, 2019

David J. Straus, MD, discusses the toxicities associated with the combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with stage III/IV classical Hodgkin lymphoma, according to data from the 3-year update of the ECHELON-1 trial presented at the 2019 ASCO Annual Meeting.